Research programme: tuberculosis vaccines - Aeras/Create Vaccine/NIBIO

Drug Profile

Research programme: tuberculosis vaccines - Aeras/Create Vaccine/NIBIO

Alternative Names: Recombinant human parainfluenza type-2 vector tuberculosis vaccine; rhPIV2 vector tuberculosis vaccine - NIBIO/Create Vaccine/Aeras

Latest Information Update: 30 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Biomedical Innovation
  • Developer Aeras; Create Vaccine Company; National Institute of Biomedical Innovation
  • Class DNA vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 26 Dec 2013 NIBIO, Aeras and Create Vaccines collaborate to develop mucosal tuberculosis vaccines
  • 26 Dec 2013 Preclinical trials in Tuberculosis in Japan (Intranasal)
  • 07 Nov 2013 NIBIO, Create Vaccine and Aeras receive grant from Global Health Innovative Technology Fund for Tuberculosis vaccine development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top